1. Home
  2. DSS vs MBIO Comparison

DSS vs MBIO Comparison

Compare DSS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DSS

DSS Inc.

HOLD

Current Price

$0.57

Market Cap

5.3M

ML Signal

HOLD

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.66

Market Cap

5.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DSS
MBIO
Founded
1984
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
5.6M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
DSS
MBIO
Price
$0.57
$0.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
59.1K
37.3K
Earning Date
05-15-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
42.45
98.99
EPS
N/A
N/A
Revenue
$2,085,000.00
N/A
Revenue This Year
$1.21
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.53
52 Week High
$1.90
$2.37

Technical Indicators

Market Signals
Indicator
DSS
MBIO
Relative Strength Index (RSI) 49.54 45.93
Support Level $0.51 $0.64
Resistance Level $1.05 $0.82
Average True Range (ATR) 0.05 0.05
MACD -0.00 -0.00
Stochastic Oscillator 40.44 42.26

Price Performance

Historical Comparison
DSS
MBIO

About DSS DSS Inc.

DSS Inc is operating a business focused on four operating segments: Product Packaging, Biotechnology, Commercial Lending, and Securities and Investment Management. Currently operates five distinct business lines that operate around the globe with primary operations in North America and Asia. Product packaging manufactures and sells sophisticated custom folding cartons, mailers, photo sleeves, and complex three-dimensional direct mail solutions. The biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the Securities and Investment Management.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: